The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma
AbstractThe prognosis of esophageal cancers is poor and novel approaches are urgently needed. Despite improvements in outcomes with transtuzumab and ramucirumab, these improvements added an average of only 2 to 3 months with a median overall survival reported to be around 1 year. Comprehensive genomic sequencing has defined some molecular alterations with potential targets, but the majority of patients still do not benefit from druggable targets. Breakthroughs in immune checkpoint blockade have provided new therapeutic options in many cancers. Programmed death ligand 1 (PDL1) overexpression, a possible biomarker predicting response to immune checkpoint inhibitors, approaches forty percent in esophageal and gastric cancers. Translational and molecular studies have shown that esophageal cancers are possible candidate malignancies for immune checkpoint inhibition. In this review, we plan to highlight the mechanisms, preclinical, and early clinical data that provide insight on the role of immune therapeutics in esophageal cancers. View Full-Text
Share & Cite This Article
Shaib, W.L.; Nammour, J.P.A.; Gill, H.; Mody, M.; Saba, N.F. The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma. J. Clin. Med. 2016, 5, 100.
Shaib WL, Nammour JPA, Gill H, Mody M, Saba NF. The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma. Journal of Clinical Medicine. 2016; 5(11):100.Chicago/Turabian Style
Shaib, Walid L.; Nammour, Jean P.A.; Gill, Harpaul; Mody, Mayur; Saba, Nabil F. 2016. "The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma." J. Clin. Med. 5, no. 11: 100.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.